| Literature DB >> 26044455 |
Dennis Wetzl1, Marco Berrera1,2, Nicolas Sandon1, Dan Fishlock1, Martin Ebeling1,2, Michael Müller3, Steven Hanlon1, Beat Wirz1, Hans Iding4.
Abstract
Recent investigations on imine reductases (IREDs) have enriched the toolbox of potential catalysts for accessing chiral amines, which are important building blocks for the pharmaceutical industry. Herein, we describe the characterization of 20 new IREDs. A C-terminal domain clustering of the bacterial protein-sequence space was performed to identify the novel IRED candidates. Each of the identified enzymes was characterized against a set of nine cyclic imine model substrates. A refined clustering towards putative active-site residues was performed and was consistent both with our screening and previously reported results. Finally, preparative scale experiments on a 100 mg scale with two purified IREDs, IR_20 from Streptomyces tsukubaensis and IR_23 from Streptomyces vidiochromogenes, were carried out to provide (R)-2-methylpiperidine in 98% ee (71% yield) and (R)-1-methyl-1,2,3,4-tetrahydroisoquinoline in >98% ee (82% yield).Entities:
Keywords: asymmetric catalysis; biocatalysis; chiral amines; imine reductases; oxidoreductases
Mesh:
Substances:
Year: 2015 PMID: 26044455 DOI: 10.1002/cbic.201500218
Source DB: PubMed Journal: Chembiochem ISSN: 1439-4227 Impact factor: 3.164